Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer.
about
Emerging therapeutic targets in esophageal adenocarcinomaDefinitive, Preoperative, and Palliative Radiation Therapy of Esophageal CancerSquamous cell carcinoma antigen (SCCA) is up-regulated during Barrett's carcinogenesis and predicts esophageal adenocarcinoma resistance to neoadjuvant chemotherapyDoes the timing of esophagectomy after chemoradiation affect outcome?Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma.Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer.Meta-analysis of postoperative efficacy in patients receiving chemoradiotherapy followed by surgery for resectable esophageal carcinoma.Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer.A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma.The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinomaPatients' Preferences for Surgical Management of Esophageal Cancer: A Discrete Choice Experiment.Vitamin D receptor expression and neoadjuvant therapy in esophageal adenocarcinomaTrimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stageĀ II/III esophageal squamous cell carcinoma patients.Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.Impact of Treatment Modalities on Survival of Patients With Locoregional Esophageal Squamous-Cell Carcinoma in Taiwan.A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer.Recurrence risk after Ivor Lewis oesophagectomy for cancerMonitoring tumour response during chemo-radiotherapy: a parametric method using FDG-PET/CT images in patients with oesophageal cancer.Update on staging and surgical treatment options for esophageal cancer.Endoscopic management of esophageal cancer after definitive chemoradiotherapy.Assessment of short-term clinical outcomes following salvage esophagectomy for the treatment of esophageal malignancy: systematic review and pooled analysis.Quality Management and Key Performance Indicators in Oncologic Esophageal Surgery.Operative and survival outcomes in a series of 100 consecutive cases of robot-assisted transhiatal esophagectomies.Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management.Which factors are associated with extremely short-term survival after surgery in patients with esophageal squamous cell carcinoma?Improving Adherence to Cancer Treatment by Addressing Quality of Life in Patients With Advanced Gastrointestinal Cancers.Esophageal cancer treated by endoscopic submucosal dissection after neoadjuvant chemoradiotherapy: a case report.Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.Defining a positive circumferential resection margin in oesophageal cancer and its implications for adjuvant treatment.Hypoxia-regulated gene expression and prognosis in loco-regional gastroesophageal cancer.[Timing of esophagectomy in multimodal therapy of esophageal cancer: Impact of time interval between neoadjuvant therapy and surgery on outcome and response].The impact of neoadjuvant chemoradiotherapy on perioperative outcomes, tumor pathology, and survival in clinical stage II and III esophageal cancer.Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals.Prospective comparison of MR with diffusion-weighted imaging, endoscopic ultrasound, MDCT and positron emission tomography-CT in the pre-operative staging of oesophageal cancer: results from a pilot study.Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.A structured training program for minimally invasive esophagectomy for esophageal cancer- a Delphi consensus study in Europe.Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer.Utility of dysphagia grade in predicting endoscopic ultrasound T-stage of non-metastatic esophageal cancer.Surveillance or resection after chemoradiation in esophageal cancer.
P2860
Q26751209-489F4090-2502-49FE-A44D-690D246F6666Q26753864-0135C337-6E96-4B83-82E3-D9F50C85C4E1Q33648496-0ACD6B54-06B1-4677-84A6-0A0FD8A205E5Q33699376-A209EF78-DA4A-48EE-BBD1-50DC1F33C954Q34039184-D270095C-ED52-4601-8ABB-78BE74A41BE2Q34135956-4537535E-A4C4-414A-83A7-6AB97907B441Q34143984-B4D3B0FB-D583-45C9-9825-214241A3145BQ34469077-D4975D9B-BAE9-44D5-9083-3B3A4BE07D07Q35375231-ED6602B8-EF1C-4B5E-976C-628BAC307F09Q35820777-B90D6CD7-0777-4D97-B10A-687C8B3865AEQ35879893-D58BB7DA-9753-4162-93D3-51E029D7C6E6Q36011121-4409BC16-7A36-4897-BB19-0566703341BAQ36105064-F9B35D83-5D53-45B0-94A6-02D26915DAC1Q36642770-E6864BE5-8DC7-488C-9317-7B39C0EF2C6EQ36681744-1B9EC5C8-3E43-436E-9D28-22BE88E9AAC1Q37207101-64FEDC1C-9531-490E-9E42-3F59FFB655DCQ37406693-2863B090-0719-4EAE-84BF-F53EE787E673Q37479830-6C34AACC-72B1-43D2-914E-59BD1C4D7E1BQ37681293-4CA9973E-382B-4573-8C23-ABE8101F42E9Q37864583-50B25CD0-3302-42AE-AA23-43282E7F1692Q38074582-A29FB8CC-DF4B-4B5C-8DB9-2352168015C1Q38161349-266D3805-DCBB-408A-92AE-912D85D0C496Q38547696-F8EF733F-39E1-46D2-AADB-324A75320461Q38599587-969A8209-944C-408D-B116-F848F6AE1CA5Q38831243-4E13A355-0F1E-4095-9C17-8B4BBA3585F5Q40661508-2C41CD6B-7BB2-45ED-BB6B-EE7EFBE8D555Q40938852-2B1EFDF2-1F1A-4C89-993C-5D2F6FB95C91Q43114611-09B35F74-B8FD-4262-A567-19E48D7807B3Q43550190-983F26A3-ABFD-41D2-8D9C-ED99596EBE0EQ44450908-53470793-C5BF-4E5E-94AD-7C5B9AA42B62Q44484701-E68297BF-8907-4B67-897E-12DD48E721DAQ44802763-CACC2112-E305-4D08-80BC-2015D3A72522Q44987067-501559F3-5E7C-4E7D-B1F7-A01D035C2AC8Q46002795-0F9F8152-AB27-496A-92A1-67B32EBC408AQ46599872-20C07B95-394D-455A-9477-EFAAFB316DA1Q48336173-57D32FDA-B975-4936-883E-945E92181344Q50092447-97335B2A-DF6F-4BE4-AF82-A16E94F57369Q51065572-E222680B-691D-43A2-B4E5-AE459AFD55E4Q52916114-29DE9381-2584-496F-8634-08A8CB311ECDQ53073167-72526251-AA87-47C6-85B6-3D2F9D2C3CA5
P2860
Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer.
description
article cientĆfic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo cientĆfico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedeckĆ½ ÄlĆ”nok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vÄdeckĆ½ ÄlĆ”nek
@cs
name
Systematic review of the benef ...... iation for oesophageal cancer.
@en
Systematic review of the benef ...... iation for oesophageal cancer.
@nl
type
label
Systematic review of the benef ...... iation for oesophageal cancer.
@en
Systematic review of the benef ...... iation for oesophageal cancer.
@nl
prefLabel
Systematic review of the benef ...... iation for oesophageal cancer.
@en
Systematic review of the benef ...... iation for oesophageal cancer.
@nl
P2093
P2860
P356
P1476
Systematic review of the benef ...... iation for oesophageal cancer.
@en
P2093
B M P Aleman
E F W Courrech Staal
H van Tinteren
J W van Sandick
M-L F van Velthuysen
P2860
P304
P356
10.1002/BJS.7175
P407
P577
2010-10-01T00:00:00Z